Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Acquisitions & Divestments (2022 - 2025)

Tarsus Pharmaceuticals has reported Change in Acquisitions & Divestments over the past 4 years, most recently at $92.1 million for Q4 2025.

  • Quarterly results put Change in Acquisitions & Divestments at $92.1 million for Q4 2025, up 159.64% from a year ago — trailing twelve months through Dec 2025 was $361.8 million (up 395.62% YoY), and the annual figure for FY2025 was $361.8 million, up 395.62%.
  • Change in Acquisitions & Divestments for Q4 2025 was $92.1 million at Tarsus Pharmaceuticals, down from $99.5 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for TARS hit a ceiling of $99.5 million in Q3 2025 and a floor of $2.5 million in Q1 2024.
  • Median Change in Acquisitions & Divestments over the past 4 years was $40.3 million (2023), compared with a mean of $47.3 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: plummeted 93.8% in 2024 and later surged 3548.72% in 2025.
  • Tarsus Pharmaceuticals' Change in Acquisitions & Divestments stood at $5.3 million in 2022, then skyrocketed by 235.84% to $17.8 million in 2023, then soared by 98.68% to $35.5 million in 2024, then soared by 159.64% to $92.1 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $92.1 million (Q4 2025), $99.5 million (Q3 2025), and $79.0 million (Q2 2025) per Business Quant data.